TGFBR1*6A and cancer risk:: A meta-analysis of seven case-control studies
TGFBR1*6A and cancer risk:: A meta-analysis of seven case-control studies
复制标题
DOI：
10.1200/jco.2003.11.524
复制
发表时间：
2003-09-01
影响因子：
45.3
通讯作者：
Pasche, B
中科院分区：
文献类型：
--
作者：
Kaklamani, VG;Hou, NJ;Pasche, B
目的：TGFBR1*6A 是 I 型转化生长因子 β 受体 (TGFBR1) 的亚等位多态性等位基因。 TGFBR1*6A 是一种候选肿瘤易感性等位基因，与各种类型癌症的发病率增加有关。本研究旨在分析所有已发表的有关 TGFBR1*6A 和癌症的病例对照研究，并确定 TGFBR1*6A 是否与癌症相关。患者和方法：纳入了所有已发表的评估 TGFBR1*6A 种系频率的病例对照研究。评估肿瘤中 TGFBR1*6A 的研究被排除在外。汇总并分析了包含 2,438 例病例和 1,846 名对照的七项研究的结果。结果：总体而言，TGFBR1*6A 携带者患癌症的风险增加 26%（比值比 [OR]，1.26；95% 置信区间 [Cl]，1.07 至 1.49）。 TGFBR1*6A 纯合子（OR，2.53；95% CI，1.39 至 4.61）的癌症风险是 TGFBR1*6A 杂合子（OR，1.26；95% CI，1.04 至 1.51）的两倍。对各类肿瘤的分析表明，TGFBR1*6A携带者患乳腺癌（OR，1.48；95% CI，1.11至1.96）、血液恶性肿瘤（OR，1.70；95% CI，1.13至2.54）和卵巢癌（OR，1.53；95% CI，1.07至2.54）的风险增加。 2.17）。来自美国的 TGFBR1*6A 携带者患结直肠癌的风险增加（OR，1.38；95% CI，1.02 至 1.86）。然而，南欧 TGFBR1*6A 携带者结直肠癌风险并未增加。 TGFBR1*6A 与膀胱癌之间没有关联。结论：TGFBR1*6A 正在成为一种高频、低外显率的肿瘤易感性等位基因，易导致乳腺癌、卵巢癌、结直肠癌以及血液系统恶性肿瘤的发生。 (C) 2003 年，美国临床肿瘤学会。
Purpose : TGFBR1*6A is a hypomorphic polymorphic allele of the type I transforming growth factor beta receptor (TGFBR1). TGFBR1*6A is a candidate tumor susceptibility allele that has been associated with an increased incidence of various types of cancer. This study was undertaken to analyze all published case-control studies on TGFBR1*6A and cancer and determine whether TGFBR1*6A is associated with cancer.Patients and Methods: All published case-control studies assessing the germline frequency of TGFBR1*6A were included. Studies assessing TGFBR1*6A in tumors were excluded. The results of seven studies comprising 2,438 cases and 1,846 controls were pooled and analyzed.Results: Overall, TGFBR1*6A carriers have a 26% increased risk of cancer (odds ratio [OR], 1.26; 95% confidence interval [Cl], 1.07 to 1.49). Cancer risk for TGFBR1*6A homozygotes (OR, 2.53; 95% CI, 1.39 to 4.61) is twice that of TGFBR1*6A heterozygotes (OR, 1.26; 95% Cl, 1.04 to 1.51). Analysis of various types of tumors shows that TGFBR1*6A carriers are at increased risk of developing breast cancer (OR, 1.48; 95% Cl, 1.11 to 1.96), hematological malignancies (OR, 1.70; 95% CI, 1.13 to 2.54), and ovarian cancer (OR, 1.53; 95% CI, 1.07 to 2.17). Carriers of TGFBR1*6A who are from the United States are at increased risk of colorectal cancer (OR, 1.38; 95% CI, 1.02 to 1.86). However, Southern European TGFBR1*6A carriers have no increased colorectal cancer risk. There is no association between TGFBR1*6A and bladder cancer.Conclusion: TGFBR1*6A is emerging as a high-frequency, low-penetrance tumor susceptibility allele that predisposes to the development of breast, ovarian, and colorectal cancer, as well as hematologic malignancies. (C) 2003 by American Society of Clinical Oncology.